Related references
Note: Only part of the references are listed.Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine
Amir Sarayani et al.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2021)
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
Miguel Angel Martinez
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Philippe Colson et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Barnaby Edward Young et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option
Tian-Tian Yao et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Roujian Lu et al.
LANCET (2020)
COVID-19 and the cardiovascular system
Ying-Ying Zheng et al.
NATURE REVIEWS CARDIOLOGY (2020)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Guangdi Li et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury
Yingxia Liu et al.
SCIENCE CHINA-LIFE SCIENCES (2020)
COVID-19 in a designated infectious diseases hospital outside Hubei Province, China
Qingxian Cai et al.
ALLERGY (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
Christian A. Devaux et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief
Azfar Athar Ishaqui et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2020)
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Lisi Deng et al.
JOURNAL OF INFECTION (2020)
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Philippe Gautret et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lei Fang et al.
LANCET RESPIRATORY MEDICINE (2020)
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Ehud Chorin et al.
NATURE MEDICINE (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Drug Evaluation during the Covid-19 Pandemic
Benjamin N. Rome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Leon Caly et al.
ANTIVIRAL RESEARCH (2020)
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Ka-Tim Choy et al.
ANTIVIRAL RESEARCH (2020)
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Robert Verity et al.
LANCET INFECTIOUS DISEASES (2020)
Macrolides in critically ill patients with Middle East Respiratory Syndrome
Yaseen M. Arabi et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process
Dat Huu Tran et al.
JOURNAL OF ANTIBIOTICS (2019)
Azithromycin Protects against Zika Virus Infection by Upregulating Virus-Induced Type I and III Interferon Responses
Chunfeng Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Pharmacist role in vaccination: Evidence and challenges
Arjun Poudel et al.
VACCINE (2019)
Fake News: Medicines Misinformation by the Media
Jackson Thomas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial
Nelson Lee et al.
ANTIVIRAL RESEARCH (2017)
Zika virus cell tropism in the developing human brain and inhibition by azithromycin
Hanna Retallack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
Jean-Marc Rolain et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus
S Åkerström et al.
JOURNAL OF VIROLOGY (2005)
Share Paper
